#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.
All content for Next Sequence is the property of Loretta TIOIELA and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.
TechBio Founders #27: Re-imagining therapeutics within the timeframe of weeks and not years through AI-based design and a high-throughput drug discovery of mini proteins with Chris BAHL, CSO at AI Proteins
Next Sequence
58 minutes 33 seconds
1 year ago
TechBio Founders #27: Re-imagining therapeutics within the timeframe of weeks and not years through AI-based design and a high-throughput drug discovery of mini proteins with Chris BAHL, CSO at AI Proteins
AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.
Next Sequence
#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.
